Rubius Therapeutics, Inc. has announced the hiring of two key company leaders, David Epstein and Torben Straight Nissen, to accelerate development of new medicines from the company's potentially revolutionary new product platform: Red-Cell Therapeutics™ (RCTs). Specifically, Epstein is joining as chairman of the board and Straight Nissen as president of the company. David Epstein, former CEO of Novartis Pharmaceuticals, has joined to serve as a Chairman of the Board. He will also will be serving in the newly created role of Executive Partner for Flagship Pioneering. At Novartis, Epstein was responsible for leading the development and commercialization of over 30 new medicines including breakthroughs such as Glivec, Gilenya, Cosentyx and Entresto. As President of Rubius, Torben Straight Nissen, brings 20 years of deep scientific knowledge and business experience to expand the company's platform and clinical programs. Torben joins Rubius from Pfizer, where he held multiple scientific and business leadership roles to advance the company's therapeutic innovation, research and development.